XPOVIO (selinexor) — Topline data
H2 2026
Topline data from the Phase 2 SENTRY-2 60 mg cohort expected in the second half of 2026.Source filing
KPTI biotech catalysts & pipeline
KARYOPHARM THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
XPOVIO (selinexor) — Filing acceptance
Q4 2026
The Company expects to receive notice of the FDA's decision on sNDA filing acceptance and, if accepted, the anticipated review timelines in the fourth quarter of 2026, following the FDA's 60-day filing review period.Source filing